Introduction: We characterized the role of aminoacyl-tRNA synthetase-interacting multifunctional protein 1 (AIMP1) in retinal inflammation and apoptosis regulation, both in vivo and in vitro. In addition, we used clinical specimens to show the relationship between AIMP1 and the development of diabetic retinopathy (DR). Objective: To elucidate the role of AIMP1 in DR. Methods: A diabetic AIMP1-specific knockout (KO) C57 mouse model was used. Human retinal microvascular endothelial cells (HRMECs) were incubated with normal glucose, high glucose (HG), and HG + AIMP1-small interfering RNA (siRNA). The expression of AIMP1 and relative inflammatory and apoptotic cytokines in diabetic mice retina and HRMECs were measured using Western blotting and polymerase chain reaction. The apoptosis of HRMECs was detected by terminal deoxynucleotidyl transferase dUTP nick end labeling assay. The levels of AIMP1 in the vitreous humor and serum were determined using ELISA. Possible correlations between the intravitreal level of AIMP1 and blood glucose, glycosylated hemoglobin HbA1c, intravitreal levels of IL-1β, and caspase-3 were determined. Results: The expression of inflammatory and apoptotic proteins was inhibited in the AIMP1 KO mice and HRMECs incubated with AIMP1-siRNA. The apoptosis of HRMECs was decreased in the AIMP1-siRNA group. The intravitreal level of AIMP1 in DR patients was significantly higher than that in nondiabetic patients (p < 0.01). There was a positive correlation between intravitreal AIMP1 and HbA1c and intravitreal IL-1β and caspase-3 (p < 0.05). Conclusions: HG induced increased expression of AIMP1 in HRMECs and retinas from diabetic C57 mice, thereby increasing the expression of inflammatory and apoptotic cytokines, which promoted DR progression. A decrease in AIMP1 expression prevented the development of DR by inhibiting the activation of inflammatory and apoptotic signaling. Therefore, AIMP1 is an effective interfering target for the prevention and treatment of DR.

1.
Klein
BE
.
Overview of epidemiologic studies of diabetic retinopathy
.
Ophthalmic Epidemiol
.
2007
Jul-Aug
;
14
(
4
):
179
83
.
[PubMed]
0928-6586
2.
Yang
DC
,
Garcia
JV
,
Johnson
YD
,
Wahab
S
.
Multienzyme complexes of mammalian aminoacyl-tRNA synthetases
.
Curr Top Cell Regul
.
1985
;
26
:
325
35
.
[PubMed]
0070-2137
3.
Kaminska
M
,
Deniziak
M
,
Kerjan
P
,
Barciszewski
J
,
Mirande
M
.
A recurrent general RNA binding domain appended to plant methionyl-tRNA synthetase acts as a cis-acting cofactor for aminoacylation
.
EMBO J
.
2000
Dec
;
19
(
24
):
6908
17
.
[PubMed]
0261-4189
4.
Kim
Y
,
Shin
J
,
Li
R
,
Cheong
C
,
Kim
K
,
Kim
S
.
A novel anti-tumor cytokine contains an RNA binding motif present in aminoacyl-tRNA synthetases
.
J Biol Chem
.
2000
Sep
;
275
(
35
):
27062
8
.
[PubMed]
0021-9258
5.
Kwon
HS
,
Park
MC
,
Kim
DG
,
Cho
K
,
Park
YW
,
Han
JM
, et al.
Identification of CD23 as a functional receptor for the proinflammatory cytokine AIMP1/p43
.
J Cell Sci
.
2012
Oct
;
125
(
Pt 19
):
4620
9
.
[PubMed]
0021-9533
6.
Kim
MS
,
Kim
TS
.
Aminoacyl tRNA Synthetase-Interacting Multifunctional Protein 1 Acts as a Novel B Cell-Activating Factor In Vitro and In Vivo
.
J Immunol
.
2015
May
;
194
(
10
):
4729
36
.
[PubMed]
0022-1767
7.
Kim
E
,
Kim
SH
,
Kim
S
,
Cho
D
,
Kim
TS
.
AIMP1/p43 protein induces the maturation of bone marrow-derived dendritic cells with T helper type 1-polarizing ability
.
J Immunol
.
2008
Mar
;
180
(
5
):
2894
902
.
[PubMed]
0022-1767
8.
Park
H
,
Park
SG
,
Lee
JW
,
Kim
T
,
Kim
G
,
Ko
YG
, et al.
Monocyte cell adhesion induced by a human aminoacyl-tRNA synthetase-associated factor, p43: identification of the related adhesion molecules and signal pathways
.
J Leukoc Biol
.
2002
Feb
;
71
(
2
):
223
30
.
[PubMed]
0741-5400
9.
Boespflug-Tanguy
O
,
Aubourg
P
,
Dorboz
I
,
Bégou
M
,
Giraud
G
,
Sarret
C
, et al.
Neurodegenerative disorder related to AIMP1/p43 mutation is not a PMLD
.
Am J Hum Genet
.
2011
Mar
;
88
(
3
):
392
3
.
[PubMed]
0002-9297
10.
Park
SG
,
Shin
H
,
Shin
YK
,
Lee
Y
,
Choi
EC
,
Park
BJ
, et al.
The novel cytokine p43 stimulates dermal fibroblast proliferation and wound repair
.
Am J Pathol
.
2005
Feb
;
166
(
2
):
387
98
.
[PubMed]
0002-9440
11.
Chen
W
,
Zhao
M
,
Zhao
S
,
Lu
Q
,
Ni
L
,
Zou
C
, et al.
Activation of the TXNIP/NLRP3 inflammasome pathway contributes to inflammation in diabetic retinopathy: a novel inhibitory effect of minocycline
.
Inflamm Res
.
2017
Feb
;
66
(
2
):
157
66
.
[PubMed]
1023-3830
12.
Rajamani
U
,
Jialal
I
.
Erratum to “Hyperglycemia Induces Toll-Like Receptor-2 and -4 Expression and Activity in Human Microvascular Retinal Endothelial Cells: Implications for Diabetic Retinopathy”
.
J Diabetes Res
.
2016
;
2016
:
8976945
.
[PubMed]
2314-6745
13.
Rajamani
U
,
Jialal
I
.
Hyperglycemia induces Toll-like receptor-2 and -4 expression and activity in human microvascular retinal endothelial cells: implications for diabetic retinopathy
.
J Diabetes Res
.
2014
;
2014
:
790902
.
[PubMed]
2314-6745
14.
Kerur
N
,
Hirano
Y
,
Tarallo
V
,
Fowler
BJ
,
Bastos-Carvalho
A
,
Yasuma
T
, et al.
TLR-independent and P2X7-dependent signaling mediate Alu RNA-induced NLRP3 inflammasome activation in geographic atrophy
.
Invest Ophthalmol Vis Sci
.
2013
Nov
;
54
(
12
):
7395
401
.
[PubMed]
0146-0404
15.
Zheng
Z
,
Chen
H
,
Li
J
,
Li
T
,
Zheng
B
,
Zheng
Y
, et al.
Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin
.
Diabetes
.
2012
Jan
;
61
(
1
):
217
28
.
[PubMed]
0012-1797
16.
Zheng
Z
,
Chen
H
,
Ke
G
,
Fan
Y
,
Zou
H
,
Sun
X
, et al.
Protective effect of perindopril on diabetic retinopathy is associated with decreased vascular endothelial growth factor-to-pigment epithelium-derived factor ratio: involvement of a mitochondria-reactive oxygen species pathway
.
Diabetes
.
2009
Apr
;
58
(
4
):
954
64
.
[PubMed]
0012-1797
17.
Zheng
Z
,
Chen
H
,
Wang
H
,
Ke
B
,
Zheng
B
,
Li
Q
, et al.
Improvement of retinal vascular injury in diabetic rats by statins is associated with the inhibition of mitochondrial reactive oxygen species pathway mediated by peroxisome proliferator-activated receptor gamma coactivator 1alpha
.
Diabetes
.
2010
Sep
;
59
(
9
):
2315
25
.
[PubMed]
0012-1797
18.
Zambrowicz
BP
,
Friedrich
GA
,
Buxton
EC
,
Lilleberg
SL
,
Person
C
,
Sands
AT
.
Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells
.
Nature
.
1998
Apr
;
392
(
6676
):
608
11
.
[PubMed]
0028-0836
19.
Park
SG
,
Kang
YS
,
Kim
JY
,
Lee
CS
,
Ko
YG
,
Lee
WJ
, et al.
Hormonal activity of AIMP1/p43 for glucose homeostasis
.
Proc Natl Acad Sci USA
.
2006
Oct
;
103
(
40
):
14913
8
.
[PubMed]
0027-8424
20.
Xu
H
,
Malinin
NL
,
Awasthi
N
,
Schwarz
RE
,
Schwarz
MA
.
The N terminus of pro-endothelial monocyte-activating polypeptide II (EMAP II) regulates its binding with the C terminus, arginyl-tRNA synthetase, and neurofilament light protein
.
J Biol Chem
.
2015
Apr
;
290
(
15
):
9753
66
.
[PubMed]
0021-9258
21.
Zhu
X
,
Liu
Y
,
Yin
Y
,
Shao
A
,
Zhang
B
,
Kim
S
, et al.
MSC p43 required for axonal development in motor neurons
.
Proc Natl Acad Sci USA
.
2009
Sep
;
106
(
37
):
15944
9
.
[PubMed]
0027-8424
22.
Hong
SH
,
Cho
JG
,
Yoon
KJ
,
Lim
DS
,
Kim
CH
,
Lee
SW
, et al.
The antibody atliximab attenuates collagen-induced arthritis by neutralizing AIMP1, an inflammatory cytokine that enhances osteoclastogenesis
.
Biomaterials
.
2015
Mar
;
44
:
45
54
.
[PubMed]
0142-9612
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.